2026-04-13T01:42:08Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/107342025-10-24T08:28:42Zcom_2072_451660com_2072_378040com_2072_378070col_2072_451662col_2072_378092
RECERCAT
author
Cordoba, Julian
author
Rodriguez-Vida, Alejo
author
Marmolejo Castañeda, David Humberto
author
Perez Marquez, Meritxell
author
Picola Brau, Natalia
author
Costa Planells, Marc
2025-10-24T08:28:42Z
2025-10-24T08:28:42Z
2023-12-20T11:47:04Z2023-12-20T11:47:04Z2023-12-08
http://hdl.handle.net/11351/10734
Apalutamide; Metastatic hormone-sensitive prostate cancer; Prostate cancerApalutamida; Cáncer de próstata metastásico sensible a hormonas; Cáncer de prostataApalutamida; Càncer de pròstata metastàtic sensible a les hormones; Càncer de pròstataObjective: To evaluate the efficacy and safety of apalutamide prostate cancer compared to the pivotal trials patients and to identify the first subsequent therapy in a real-world setting.
Methods: The study is prospective and observational based on real-world evidence, performed by different medical disciplines and eight academics centres around Barcelona, Spain. It included all patients with metastatic hormone-sensitive prostate cancer (mHSPC) and high-risk non-metastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide from June 2018 to December 2022.
Results: Of 227 patients treated with apalutamide, 10% had ECOG-PS 2, and 41% were diagnosed with new-generation imaging. In the mHSPC group (209 patients), 75 years was the median age, 53% had synchronous metastases, and 22% were M1a. In the nmCRPC (18 patients), 82 years was the median age, and 81% ≤6 months had PSA doubling time. Patients achieved PSA90 in 92% of mHSPC and 50% of nmCRPC and PSA ≤0.2 in 71% of mHSPC and 39% of nmCRPC. Treatment-related adverse events occurred in 40.1% of mHSPC and 44.4% of nmCRPC. After discontinuation of apalutamide due to disease progression, 54.5% in mHSPC and 75% in nmCRPC started chemotherapy, while after discontinuation because of adverse events, 73.3% in mHSPC and 100% in nmCRPC continued with other hormonal-therapies.This study did not receive funding. Julián Córdoba and Meritxell Pérez have received sponsorship from Janssen for medical congresses and symposiums. Alejo Rodriguez- Vida, Jesús Muñoz Rodriguez, Antonio Alcaraz and Antoni Vilaseca have received honoraria from Janssen for advisory board meetings, symposiums and travel ex-penses. The other authors declare no conflict of interest. Approval of the research protocol by an Institutional Reviewer Board: HCB/2019/0919.
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess
Hormones
Antigen prostàtic específic
Pròstata - Càncer
DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms
CHEMICALS AND DRUGS::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones
CHEMICALS AND DRUGS::Enzymes and Coenzymes::Enzymes::Hydrolases::Peptide Hydrolases::Endopeptidases::Serine Endopeptidases::Kallikreins::Prostate-Specific Antigen
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata
COMPUESTOS QUÍMICOS Y DROGAS::hormonas, sustitutos de hormonas y antagonistas de hormonas::hormonas
COMPUESTOS QUÍMICOS Y DROGAS::enzimas y coenzimas::enzimas::hidrolasas::péptido hidrolasas::endopeptidasas::serina endopeptidasas::calicreínas::antígeno prostático específico
Apalutamide for prostate cancer: multicentre and multidisciplinary real-world study of 227 patients
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion